Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep 2003 ;5:342-6SadafTaimur, Martin J.Edelman. (2003) Treatment options for brain metastases in patients with non-small cell lung cancer. Current Treatment Options in Oncology 4 , 89-95 /...
Management Options for Stage IV Breast Cancer Metastatic to the Brain? Question A 42-year-old woman was treated 3 years ago with mastectomy, irradiation, and 4 cycles of doxorubicin/cyclophosphamide for an ER-negative, HER-2/neu-positive ductal carcinoma. Disease recurred 1 year ago with skelet...
The fluid can be checked for signs of infection or cancer cells.In rare cases, doctors may want to remove a small piece of tumor tissue before diagnosing the cancer. This is called a biopsy.Treatment optionsThe following list of medications are related to or used in the treatment of this ...
Preclinical approaches involving NK cells for the treatment of brain tumors focus on three modes of action. Tumor-mediated antigen activation includes the activation of NK cell activity by cancer cell antigen recognition. Recognition of stress antigens, expressed as a result of bortezomib treatment, c...
treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of...
For example, although variations in screening and the stage at which the primary tumor is diagnosed are also likely to contribute, the median time for patients with breast cancer to develop brain metastases was 44 months, compared with 11 months for lung cancer. Molecular subtype of primary ...
Glioblastoma Translational Center of Excellence, The Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Zev A. Binder, MacLean P. Nasrallah, Donald M. O’Rourke & Hongjun Song Institute for Regenerative Medicine, University of Pennsylvania, Philadelphi...
Glioblastoma multiforme (GBM), an extremely invasive and high-grade (grade IV) glioma, is the most common and aggressive form of brain cancer. It has a poor prognosis, with a median overall survival of only 11 months in the general GBM population and 14.
Brain scans of a 72-year-old man diagnosed with a highly aggressive form of cancer known as a glioblastoma have revealed a remarkable regression in his tumor's size within days of receiving an infusion of an innovative new treatment.
Bao Ming QIN, Cell Res, 2005 Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of... Wen-Zhao Zhong, Signal Transduction and Targeted Therapy, 2023 Clinical efficacy and identification of fac...